Regeneron to present Ordspono trial results in relapsed or refractory marginal zone lymphoma at ASH
REGN•Regeneron will present hematology data across 14 abstracts at the American Society of Hematology meeting, Dec. 12-15, 2026, in New Orleans. Ordspono’s primary analysis in relapsed or refractory marginal zone lymphoma is scheduled for Dec. 14.
1. ASH presentations
Regeneron said it will present hematology data across 14 abstracts at ASH, Dec. 12-15, 2026, in New Orleans. The Ordspono ELM-2 primary analysis in relapsed or refractory marginal zone lymphoma, which the company describes as potentially registration-supporting, is scheduled for Dec. 14.
2. Other study results
Longer-term results from the LINKER-AL2 study of Lynozyfic in relapsed or refractory systemic light chain amyloidosis will be presented Dec. 12, building on previously reported efficacy. A separate analysis will compare cemdisiran-pozelimab with ravulizumab in paroxysmal nocturnal hemoglobinuria, assessing disease control and transfusion avoidance.




